Filippo de Marinis1, Andrea Ardizzoni2, Gabriella Fontanini3, Francesco Grossi4, Federico Cappuzzo5, Silvia Novello6, Antonio Santo7, Vito Lorusso8, Diego Cortinovis9, Monica Iurlaro10, Domenico Galetta11, Cesare Gridelli12. 1. UOC Pneumologia Oncologica, A.O. San Camillo Forlanini, Rome, Italy; Thoracic Oncology Division, European Institute of Oncology (IEO), Milan, Italy. Electronic address: filippo.demarinis@ieo.it. 2. U.O. Oncologia Medica, Azienda Ospedaliera di Parma, Parma, Italy. 3. U.O. Oncologia II Univ., Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. 4. S.S. Tumori Polmonari, IRCCS A.O.U. San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. 5. Oncologia, Ospedale di Livorno - Oncologia, Livorno, Italy. 6. Oncologia, Università di Torino; A.O.U. San Luigi Gonzaga, Orbassano, Italy. 7. GIVOP (Gruppo Interdisciplinare Veronese Oncologia Polmonare), Ospedale Civile Maggiore Borgo Trento - Oncologia Medica D.O., Verona, Italy. 8. Oncologia Medica Pad. oncologico Ospedale V. Fazzi, Lecce, Italy. 9. UO Oncologia Medica Ospedale San Gerardo, Monza, Italy. 10. Boehringer Ingelheim S.p.A., Milano, Italy. 11. Oncologia Medica IRCCS Giovanni Paolo II Ospedale Oncologico, Bari, Italy. 12. Oncologia Medica, A.O.R.N. San Giuseppe Moscati, Avellino, Italy.
Abstract
INTRODUCTION/ BACKGROUND: Patients with advanced NSCLC who experience disease progression after second-line therapy might receive further active treatment. LIFE was an Italian cohort multicenter observational study composed of a cross-sectional and a longitudinal phase. PATIENTS AND METHODS: In the longitudinal phase, described here, the primary aim was to determine the proportion of patients receiving third-line therapy among those who received second-line active treatment according to clinical practice. The proportion of patients receiving further treatment lines was also estimated. RESULTS: The longitudinal phase was conducted between January and August 2012. Of 464 patients who began second-line therapy outside of clinical trials within the baseline evaluation, 56 (12.1%) were still receiving second-line therapy at the end of the observation period and 17 (3.7%) withdrew during or after second-line therapy. Of the remaining 391 patients, 158 (40.4%) received third-line treatment outside of clinical trials: 93 received a third-line chemotherapy and 65 a targeted agent. The main reason for interrupting third-line treatment was disease progression or death. During the same observation period, 25 of 113 patients who completed a third-line therapy received a fourth line of treatment. From diagnosis of NSCLC to the end of observation, biomarkers were tested in 323 patients (59.7%): epidermal growth factor receptor mutations in 315 (58.2%), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations in 83 (15.3%) and Anaplastic lymphoma kinase (ALK) translocation in 84 (15.5%). CONCLUSION: In Italian clinical practice, the proportion of patients with advanced NSCLC receiving more than 2 treatment lines of therapy is not negligible.
INTRODUCTION/ BACKGROUND:Patients with advanced NSCLC who experience disease progression after second-line therapy might receive further active treatment. LIFE was an Italian cohort multicenter observational study composed of a cross-sectional and a longitudinal phase. PATIENTS AND METHODS: In the longitudinal phase, described here, the primary aim was to determine the proportion of patients receiving third-line therapy among those who received second-line active treatment according to clinical practice. The proportion of patients receiving further treatment lines was also estimated. RESULTS: The longitudinal phase was conducted between January and August 2012. Of 464 patients who began second-line therapy outside of clinical trials within the baseline evaluation, 56 (12.1%) were still receiving second-line therapy at the end of the observation period and 17 (3.7%) withdrew during or after second-line therapy. Of the remaining 391 patients, 158 (40.4%) received third-line treatment outside of clinical trials: 93 received a third-line chemotherapy and 65 a targeted agent. The main reason for interrupting third-line treatment was disease progression or death. During the same observation period, 25 of 113 patients who completed a third-line therapy received a fourth line of treatment. From diagnosis of NSCLC to the end of observation, biomarkers were tested in 323 patients (59.7%): epidermal growth factor receptor mutations in 315 (58.2%), Kirsten ratsarcoma 2 viral oncogene homolog (KRAS) mutations in 83 (15.3%) and Anaplastic lymphoma kinase (ALK) translocation in 84 (15.5%). CONCLUSION: In Italian clinical practice, the proportion of patients with advanced NSCLC receiving more than 2 treatment lines of therapy is not negligible.
Authors: Maria Rita Migliorino; Antonio Santo; Giampiero Romano; Diego Cortinovis; Domenico Galetta; Oscar Alabiso; Giacomo Cartenì; Sabrina Vari; Gianpiero Fasola; Antonio Pazzola; Dario Giuffrida; Alberto Zaniboni; Alberto Caprioli; Flavia Longo; Valentina Acciai; Filippo de Marinis Journal: J Cancer Res Clin Oncol Date: 2017-02-18 Impact factor: 4.553
Authors: Jessica Davies; Manali Patel; Cesare Gridelli; Filippo de Marinis; Daniel Waterkamp; Margaret E McCusker Journal: PLoS One Date: 2017-04-14 Impact factor: 3.240